SCHEMBL6429372

SCHEMBL6429372

O=C1C(Cl)=C(c2ccc(Cl)cc2)C(=O)N1Cc1ccc2c(c1)OCO2

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.57
PKM P14618 2/20 0.57
TSHR P16473 2/20 0.57
KMT2A Q03164 1/20 0.57
CMA1 P23946 1/20 0.57
SCN9A Q15858 1/20 0.49
HPGD P15428 3/20 0.49
GAA P10253 1/20 0.47
LMNA P02545 4/20 0.47
PDE5A O76074 1/20 0.47
ALDH1A1 P00352 1/20 0.46
MAPK1 P28482 3/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90B1 P14625 1/20 0.46
TRAP1 Q12931 1/20 0.46
POLB P06746 2/20 0.45
CYP3A4 P08684 2/20 0.45
ABCB11 O95342 1/20 0.45
CYP1A2 P05177 1/20 0.45
ADRA2A P08913 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6430888 0.85 PKM (0.52) SMN1; SMN2PKMTSHRKMT2ACMA1
SCHEMBL6428843 0.83 NR1H2 (0.52) KMT2ASCN9ALMNAALDH1A1MAPK1
SCHEMBL6426484 0.79 APAF1 (0.52) TSHRKMT2AGAAALDH1A1HSP90B1
SCHEMBL6428883 0.77 NR1H2 (0.48) SMN1; SMN2KMT2AHPGDLMNAALDH1A1
SCHEMBL6427927 0.77 MAPT (0.52) SMN1; SMN2KMT2AHPGDGAALMNA
SCHEMBL6427000 0.76 NR1H2 (0.60) SMN1; SMN2KMT2ASCN9AHPGDLMNA
SCHEMBL6426845 0.76 MAPT (0.50) PKMKMT2AHPGDLMNAALDH1A1
SCHEMBL19500873 0.73 KMT2A (1.00) SMN1; SMN2PKMTSHRKMT2ACMA1
SCHEMBL6429547 0.73 CMA1 (0.54) KMT2ACMA1SCN9AALDH1A1MAPT
SCHEMBL1080694 0.71 CMA1 (0.76) SMN1; SMN2PKMTSHRKMT2ACMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005024755-A2 MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR DIABETES DECIPHERA PHARMACEUTICALS, LLC. (US) 2005-03-17 WO disclosed